AB 1461: Cannabis: testing laboratories.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-04-22
|
Date
|
Status
|
|---|---|
| Feb 3, 2020 | From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. |
| Jan 31, 2020 | Died pursuant to Art. IV, Sec. 10(c) of the Constitution. |
| Apr 23, 2019 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Apr 23, 2019 | Re-referred to Com. on B. & P. |
| Apr 22, 2019 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Apr 1, 2019 | Re-referred to Com. on B. & P. |
| Mar 28, 2019 | Referred to Com. on B. & P. |
| Feb 25, 2019 | Read first time. |
| Feb 23, 2019 | From printer. May be heard in committee March 25. |
| Feb 22, 2019 | Introduced. To print. |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 1461
Author:(Quirk) – As Amended Ver:April 22, 2019
SUBJECT: Cannabis: testing laboratories.
SUMMARY: Allows manufacturers to arrange for certificate of analysis testing by laboratories instead of limiting this authority only to distributors.
EXISTING LAW:
- Establishes the Bureau of Cannabis Control under the Department of Consumer Affairs to administer and enforce the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) and the Control, Regulate and Tax Adult Use of Marijuana Act of 2016 (AUMA), which establishes a comprehensive system to control and regulate the distribution, transport, storage, and sale of cannabis products. (Business and Professions Code (BPC) § 26000 et seq.)
- Requires licensed sellers of cannabis or cannabis products to have a representative sample tested by a licensed testing laboratory. (BPC § 26100)
- Authorizes a testing laboratory to receive and test samples of cannabis or cannabis products from a qualified patient or primary caregiver, only if the qualifies patient or caregiver presents the qualified patient’s valid physician’s recommendation for cannabis for medicinal purposes. Prohibits a testing laboratory from certifying samples from a qualified patient or primary caregiver for resale or transfer to another party or licensee. Requires all tests performed by a testing laboratory for a qualified patient or primary caregiver to be recorded with the name of the qualified patient or primary caregiver and the amount of cannabis or cannabis product received. (BPC § 26104 defines “certificate of analysis” as the report prepared by the laboratory about the analytical testing performed and results obtained by the laboratory. (California Code of Regulations (CCR), Title 16, § 5700(q)
- Requires a distributor after receipt of a certificate of analysis from a testing laboratory, or upon transfer from another distributor, before transporting the cannabis goods, to ensure, among other things, that the certificate is the proper certificate for the batch, is timely, is consistent with the label on the goods. (CCR, tit. 16, § 5307)
THIS BILL:
- Requires The Bureau of Cannabis Control (Bureau) to adopt regulations to establish a process authorizing testing of random batches of cannabis or cannabis products that have had testing and quality assurance performed.
- Requires that testing samples shall be collected at the licensed premises of the distributor.
- Testing shall be conducted by the same testing laboratory that issued the certificate of analysis to the manufacturer and only to determine whether the product conforms with the certificate of analysis provided to the distributor.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by Legislative Council.
COMMENTS:
Purpose. This bill is sponsored by the California Cannabis Manufacturer’s Association. According to the sponsor, “The regulated cannabis industry is at risk. The legal market has been unable to drive out the remnants of underground cannabis markets, and there are serious concerns that under the regulations as currently structured the black market may never be driven out. AB 1461 allows manufacturers to arrange for the Certificate of Analysis (COA) testing done by laboratories. Currently, distributors are the only businesses which can arrange for COA testing. Many companies which are not in the traditional business of distribution – transporting product between manufacturers and retailers – have sought distribution licenses so that they can obtain COAs on their product. Many manufacturers are licensing as distributors and operating separate distributor warehouses, sometimes right next door to their manufacturing warehouses. Manufacturers move their packaged product next door to their distributor warehouse and can then send it to a testing laboratory. This game of changing hats does not benefit consumers; it only adds unnecessary licensure and labor costs, at a time when the industry is struggling to outcompete the underground market.”
Background. Allowing manufacturers of cannabis goods to facilitate their own testing and quality assurance review poses a number of concerns for the safety and integrity of manufactured cannabis products. Under current law, a licensed distributor is tasked with transporting cannabis products to and from a testing laboratory and also conducting a quality assurance review. This ensures that an independent third-party is facilitating the process that will determine whether or not a product is safe to be sold on the open market.
By allowing a manufacturer to conduct their own testing and quality assurance review, this bill creates the potential for unsafe products to be inappropriately certified and weakens public confidence in the test results of manufactured cannabis goods. Furthermore, distributors are placed in a potentially difficult legal liability position as they “may” rely on the manufacturer’s own certification and quality assurance review. It is imperative that an independent third-party licensed distributor facilitate state certified testing to ensure non-biased testing results and safe cannabis goods. The independent reviews by distributors ensure products have a passing Certificate of Analysis (COA), are labeled according to Manufactured Cannabis Safety Branch guidelines, and meet child resistant packaging standards among many other requirements.
The Medical Marijuana Regulation and Safety Act (MMRSA), the Control, Regulate and Tax
Adult Use of Marijuana Act (AUMA), and the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), unequivocally reinforced the distributor’s imperative role in facilitating state certified testing and quality assurance review before cannabis products are sold to dispensaries. The distributor model has worked to ensure cannabis products are meeting the highest safety standards and this bill weakens this by allowing cannabis manufacturers to facilitate testing and quality assurance reviews for their own products.
Current Related Legislation. AB 404 (Stone) of the current legislative session allows a cannabis testing laboratory to amend a certificate of analysis to fix minor errors and to retest a sample if the test result falls outside the specifications authorized by law, the Bureau of Cannabis Control authorizes the test, and the test was compromised due to equipment malfunction, staff error, or other circumstances allowed by the Bureau.
AB1288 (Cooley) of the current Legislative Session, requires information captured by the cannabis “track and trace” program to include details on the date and location of retail sale to a customer, and requires the Department of Food and Agriculture, in consultation with the Bureau, to ensure that the “track and trace” program is fully integrated into the California Law Enforcement Telecommunications System by July 1, 2020.
AB1461 (Quirk) of the current Legislative Session, makes technical, non-substantive changes to the Business and Professions Code Section 26104, which describes several obligations and restrictions relating to cannabis testing laboratories.
SB153 (Wilk) of the current Legislative Session, revises provisions regulating the cultivation and testing of industrial hemp
Prior Related Legislation. SB 837 (Budget and Fiscal Review, Chapter 32, Statutes of 2016) clarified that licensed operators may test cannabis and cannabis products in-house for quality assurance purposes.
AB 243 (Wood, Chapter 688, Statutes of 2015) requires CDFA, DPR, the State Department of Public Health, the Department of Fish and Wildlife, and the State Water Resources Control Board to promulgate regulations or standards relating to medical cannabis and its cultivation, as specified, and establishes licensing fees, fines, and penalties.
AB 266 (Bonta et al., Chapter 689, Statutes of 2015) established the Act for the licensure and regulation of medical cannabis and establishes the Bureau of Medical Cannabis Regulation within the DCA.
SB 643 (McGuire, Chapter 719, Statutes of 2015) set standards for the licensed cultivation and physician prescription of medical cannabis; establishes a track and trace program for the transportation of medical cannabis; and authorizes counties to impose a tax on medical cannabis.
ARGUMENTS IN SUPPORT:
According to Southern California Coalition, “[This bill] allows cannabis manufacturers to manage testing and quality assurance in a more efficient and less expensive manner than is currently available to them. It is a badly needed adjustment of business practices. It allows the industry to move forward in a regulated but expeditious manner. The profit margin on manufactured items is often very slim and allowing business operators to manage their businesses in a safe but less expensive manner would be helpful.”
ARGUMENTS IN OPPOSITION:
According to Continuum, “[This bill] would permit a licensed cannabis manufacturer to arrange for a testing lab to obtain a representative sample of each cannabis batch from their licensed premise for purposes of state testing. In addition, [this bill] would allow a licensed manufacturer to perform quality assurance reviews of their own products.”
The Cannabis Distribution Association states “[This bill] would compromise the testing and quality assurance review process for licensed cannabis goods.”
The California Teamsters Public Affairs Council, also in opposition states, “ Allowing manufacturers of cannabis goods to facilitate their own testing and quality assurance review poses a number of concerns for the safety and integrity of manufactured cannabis products. Under current law, a licensed distributor is tasked with transporting cannabis products to and from a testing laboratory and conducting a quality assurance review. This ensures that an independent third-party is facilitating the process that will determine whether or not a product is safe to be sold on the open market.
By allowing a manufacturer to conduct their own testing and quality assurance review, [this bill] creates the potential for unsafe products to be inappropriately certified and weakens public confidence in the test results of manufactured cannabis goods.”
Voicing her CONCERN, the California State Treasurer, Fiona Ma, states “[This bill] would have California take a step backward from ensuring we have a streamlined legal cannabis market with the proper checks and balances in place to stop unsafe products from reaching California ' s regulated cannabis market. For these reasons, I respectfully voice my concerns with this current version of [this bill], and ask the author and committee to consider them as this bill moves through the process.”
POLICY ISSUE(S) FOR CONSIDERATION:
Concerns arise in regards to what happens when a distributor decides to conduct their own testing and quality assurance review on a product that passed the manufacturer’s testing and review process, if only to find out that it failed their independent testing and review process.
Allowing manufacturers of cannabis goods to facilitate their own testing and quality assurance review poses a number of concerns for the safety and integrity of manufactured cannabis products that goes against the checks and balances currently in place.
Under current law, a licensed distributor is tasked with transporting cannabis products to and from a testing laboratory and also conducting a quality assurance review. This ensures that an independent third-party is facilitating the process that will determine whether or not a product is safe to be sold on the open market. In addition, if a distributor takes a manufacturer’s certified product to market and there is a safety issue with an end-user, the question remains as to who will be liable. Distributors are placed in a potentially difficult legal liability position as they "may" rely on the manufacturer’s own certification and quality assurance review.
REGISTERED SUPPORT:
Southern California Coalition
REGISTERED OPPOSITION:
California Teamsters Public Affairs Council
Cannabis Distribution Association
Continuum Distribution
CONCERNS
Office of the State Treasurer, Fiona Ma, State Treasurer
Analysis Prepared by: Danielle Sires / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):